ArticleJournal of liver cancer2023
Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes.
Article in Journal of liver cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Agomelatine versus gefitinib against HepG2 cells: Modulating PI3K/AKT and MAPK/RAF1/c-FOS pathways.Molecular biology reports · 2026Article
- NSUN3-Mediated ROS Accumulation Promotes Hepatocellular Carcinoma Proliferation and Activates PI3K/AKT Pathway.Biochemical genetics · 2026Article
- Hepatocellular carcinoma and vitamin D metabolism: novel targets and therapeutic strategies.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Association between periodontitis and hepatocellular carcinoma across different tumor stages.BMC oral health · 2026Article
- Let-7a and miR-34a Interplay Potent Suppressive Roles in Hepatocellular Carcinoma via Co-TargetingInternational journal of molecular sciences · 2026Article
- Steroids fromMolecular biology research communications · 2026Article
- Pre- and postoperative predictors of extrahepatic recurrence after curative resection for hepatocellular carcinoma.BMC cancer · 2025Article
- Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.Journal of gastrointestinal cancer · 2025Review
- Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial.Hepatology international · 2025Article
- Comparison of initial treatments for resectable hepatocellular carcinoma within Milan criteria: an observational study based on a nationwide survey.Annals of surgical treatment and research · 2025Article
- Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies.Cancers · 2025Review
- Therapeutic potential of kakkatin derivatives against hepatocellular carcinoma.World journal of clinical oncology · 2025Article
- Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues.Scientific reports · 2024Article
- Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis.Journal of liver cancer · 2024Article
- Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer.Oncology letters · 2024Article
- Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment.Journal of liver cancer · 2024Article
- Trends in alcohol use and alcoholic liver disease in South Korea: a nationwide cohort study.BMC public health · 2024Article
- Hepatocellular carcinoma outcomes and potential implications for surveillance in elderly patients.Scientific reports · 2024Article
- Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Radiofrequency for hepatocellular carcinoma larger than 3 cm: potential for applications in daily practice.Journal of liver cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although hepatocellular carcinoma (HCC) is associated with a poor prognosis, management of early-stage HCC is often successful with highly efficacious treatment modalities such as liver transplantation, surgical resection, and radiofrequency ablation. However, unfavorable clinical outcomes have been observed under certain circumstances, even after efficient treatment. Factors that predict unsuitable results after treatment include tumor markers, inflammatory markers, imaging findings reflecting tumor biology, specific outcome indicators for each treatment modality, liver functional reserve, and the technical feasibility of the treatment modalities. Various strategies may overcome these challenges, including the application of reinforced treatment indication criteria with predictive markers reflecting tumor biology, compensation for technical issues with up-to-date technologies, modification of treatment modalities, downstaging with locoregional therapies (such as transarterial chemotherapy or radiotherapy), and recently introduced combination immunotherapies. In this review, we discuss the challenges to achieving optimal outcomes in the management of early-stage HCC and suggest strategies to overcome these obstacles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.